Yukon Choice PC Elite

Sirolimus Eluting Coronary Stent System

Technology
Clinical data
Specifications

The 1st DES to provide the synergy of Biodegradable Polymer with microporous surface protected with thermal insulation packing and electronic monitoring device for high quality and optimal performance

Setting New Standards of Quality Control

At temperatures beyond 8-25°C, Sirolimus develops oxidative degradation or Group-II impurities which may impact the potency of the drug.

To ensure protection from various environmental conditions, Yukon Choice PC Elite is equipped with Polystrene Thermal Insulation Packing.

The thermal insulated pack is further monitored by an electronic monitoring device Tag Alert manufactured by SENSITECH USA

Resources
Product Brochure

Cardiovascular Stent India
Less Polymeric Load Compared to Other DES
One million pores per cm2 with average depth of 2 µm ensures optimum drug release with 1/4th of polymeric load as compared to other DES.

Top coat with Shellac Resin ensures better polymer drug binding with negligible polymer flaking during stent expansion.

World's Longest Studied Drug Eluting Stent

2018

At 10 years, Yukon Choice PC showed equivalence in terms of MACE rate, Mortality and TLR rate compared to Xience and a superiority over Cypher for the same outcomes ……………….. CLINICAL STUDY

Yukon Choice PC showed the lowest rate of definite or probable stent thrombosis with a significant risk reduction than the Cypher stent (50% reduction) and a numerically lower rate as than the ‘Xience’ stent (29% reduction).

2018

Yukon Choice PC is recommended by ESC guidelines 2018 on the basis of large randomized trials where primary end points were achieved.
……………….. CLINICAL STUDY

2014

Yukon Choice PC showed equivalent efficacy & better safety in terms of stent thrombosis compared to Xience & Cypher at 5 years follow up.
……………….. CLINICAL STUDY

2013

At four years follow up, Yukon Choice PC demonstrated reduced rates in stent thrombosis in patients with diabetes mellitus as compared to durable polymer.
……………….. CLINICAL STUDY

2012

At four years follow up, Yukon Choice PC shows reduction of risk by 50% in Definite Stent Thrombosis & by 78% in Very Late stent thrombosis as compared to the first generation DES with similar efficacy.
……………….. CLINICAL STUDY

2011

At 3 years, Yukon Choice PC proved equivalance to Xience in terms of Late loss, TLR and Primary Composite MACE.
……………….. CLINICAL STUDY

2008

In Pre-clinical trial, it was seen that Yukon Choice PC with microporous surface reduced the amount of polymeric load to 1/4th and is assured with consistent kinetics & low inflammation.
……………….. CLINICAL STUDY

2004

At 2 years, microporous surface was found to be equally safe as compared to electropolished surface. Rough surfaces showed lesser restenosis rates.
……………….. CLINICAL STUDY

TECHNICAL DATA

PRODUCT MATRIX / ORDERING INFORMATION*

sirolimus eluting coronary stent

COMPLIANCE CHART

Share